Sarepta Therapeutics (NASDAQ:SRPT) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Sarepta Therapeutics (NASDAQ:SRPT) from a sell rating to a hold rating in a research note published on Saturday morning.

SRPT has been the subject of a number of other research reports. Barclays began coverage on Sarepta Therapeutics in a report on Wednesday, January 28th. They set an “equal weight” rating and a $20.00 price target for the company. Robert W. Baird lowered their target price on Sarepta Therapeutics from $21.00 to $15.00 and set a “neutral” rating for the company in a research note on Tuesday, November 4th. HC Wainwright restated a “sell” rating on shares of Sarepta Therapeutics in a research note on Tuesday, January 27th. Royal Bank Of Canada lifted their price target on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the company a “sector perform” rating in a report on Thursday, January 8th. Finally, Guggenheim lowered their price objective on shares of Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Nine equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $33.56.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT opened at $16.76 on Friday. The firm has a 50 day moving average of $20.43 and a 200-day moving average of $20.22. Sarepta Therapeutics has a 12 month low of $10.41 and a 12 month high of $108.48. The company has a current ratio of 2.95, a quick ratio of 1.79 and a debt-to-equity ratio of 0.78. The stock has a market capitalization of $1.76 billion, a PE ratio of -1.99, a PEG ratio of 0.42 and a beta of 0.39.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($2.71). Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 49.42%. The firm had revenue of $442.93 million during the quarter, compared to the consensus estimate of $390.95 million. During the same period last year, the business earned $1.90 earnings per share. The business’s revenue was down 32.7% compared to the same quarter last year. On average, equities research analysts predict that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Insider Activity at Sarepta Therapeutics

In related news, COO Ian Michael Estepan sold 13,187 shares of the business’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $22.31, for a total value of $294,201.97. Following the sale, the chief operating officer owned 193,300 shares of the company’s stock, valued at $4,312,523. The trade was a 6.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. CWM LLC grew its stake in shares of Sarepta Therapeutics by 4,033.3% in the 3rd quarter. CWM LLC now owns 72,705 shares of the biotechnology company’s stock valued at $1,401,000 after buying an additional 70,946 shares during the period. Aberdeen Group plc boosted its holdings in Sarepta Therapeutics by 59.6% in the third quarter. Aberdeen Group plc now owns 1,982,764 shares of the biotechnology company’s stock worth $38,208,000 after acquiring an additional 740,360 shares in the last quarter. 683 Capital Management LLC boosted its holdings in Sarepta Therapeutics by 309.1% in the second quarter. 683 Capital Management LLC now owns 675,000 shares of the biotechnology company’s stock worth $11,542,000 after acquiring an additional 510,000 shares in the last quarter. State of New Jersey Common Pension Fund D grew its stake in Sarepta Therapeutics by 59.9% in the second quarter. State of New Jersey Common Pension Fund D now owns 48,555 shares of the biotechnology company’s stock valued at $830,000 after acquiring an additional 18,190 shares during the period. Finally, Edgestream Partners L.P. increased its holdings in shares of Sarepta Therapeutics by 870.3% during the second quarter. Edgestream Partners L.P. now owns 82,979 shares of the biotechnology company’s stock valued at $1,419,000 after acquiring an additional 74,427 shares in the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics News Roundup

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Revenue beat estimates in Q4 ($442.9M vs. ~$391M consensus), which partially offsets earnings weakness and suggests underlying commercial traction outside the challenged product. Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates
• Positive Sentiment: Wells Fargo kept an “overweight” rating on SRPT, implying continued analyst conviction in the story despite lowering its price target to $38 (from $45), signaling potential upside from current levels. Wells Fargo Lowers Price Target
• Neutral Sentiment: Sarepta expanded non-market PR and community programs — opening applications for the Route 79 Duchenne scholarship — which supports brand and patient-community relations but is unlikely to move near-term valuation. Sarepta Announces Route 79 Scholarship
• Neutral Sentiment: Sarepta plans to present long-term and safety data at the upcoming MDA conference — data releases could be material but timing and contents are uncertain. Sarepta to Present Long-Term Data at MDA
• Negative Sentiment: Large Q4 EPS miss: reported EPS was far worse than consensus (reported loss −$3.58 vs. est. −$0.87), driven by a steep decline in ELEVIDYS sales and a wider net loss, increasing short-term revenue and margin uncertainty. Sarepta Q4 Earnings Report
• Negative Sentiment: CEO Douglas Ingram announced he will retire by year-end (or upon his replacement), introducing leadership transition risk at a sensitive time for product recovery and strategy execution. Reuters: Sarepta CEO Ingram to Retire
• Negative Sentiment: Institutional selling: AXQ Capital materially trimmed its SRPT stake (large percentage reduction), which can add selling pressure and signal reduced conviction among some holders. AXQ Capital Lowers Position in Sarepta

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.